Navigation Links
Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
Date:7/7/2008

BELLEVUE, Wash., July 7 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced that it has begun treatment of patients with benign prostatic hyperplasia (BPH), or enlargement of the prostate, using Light Infusion Therapy(TM) (Litx(TM)), an innovative light-activated drug treatment under development. LSO plans to conduct a 12-patient, Phase I/II dose-escalation study at four sites in the United States as well as a 40-patient, Phase IIa study in Australia, expected to begin during the current quarter.

"Treating patients with this serious quality-of-life problem is an important milestone for our Litx technology," said Llew Keltner, M.D., Ph.D., President and Chief Executive Officer of LSO. "We plan to continue to demonstrate the broader applicability of Litx beyond oncology." LSO currently is conducting Phase III clinical studies of Litx in patients with hepatoma (primary liver cancer) and metastatic colorectal cancer and expects to initiate a Phase III clinical study in glioma in the second half of 2008.

BPH is a common result of aging and is estimated to occur in more than 14 million American men. BPH rarely causes symptoms before age 40, but more than half of men in their sixties and as many as 90 percent in their seventies and eighties have some symptoms of BPH, which typically include painful and frequent urination caused by the enlarged prostate's reduction of urine flow through the urethra. Early stage treatment is critical, because severe BPH can cause serious problems over time, such as urinary tract infections, bladder stones, incontinence, and eventually untreatable bladder or kidney damage.

Litx uses light-emitting diodes (LEDs) to activate LS11 (talaporfin sodium) molecules. Once activated, these molecules cause the production of singlet oxygen, which can kill target tissues with minimal side effects through vascular closure and apoptosis, or "programmed cell death." The single-use, disposable Litx device contains a
'/>"/>

SOURCE Light Sciences Oncology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
2. June 2008 Mayo Clinic Womens HealthSource Highlights Shingles Vaccine for Pain Prevention, Tips to Avoid Antibiotic Resistant Infections, and Benefits of Broad Genetic Testing
3. New Subset Analysis of AndroGel(R) Data Highlights Efficacy - Regardless of BMI
4. Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference
5. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
6. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
9. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
10. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
11. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014  VentiRx Pharmaceuticals, Inc., a ... development and commercialization of novel Toll-like receptor ... U.S. Food and Drug Administration (FDA) has ... of motolimod (VTX-2337) when administered in combination ... treatment of women with ovarian cancer whose ...
(Date:9/2/2014)... , Sept. 2, 2014 Bluegrass ... company focused on innovating lifesaving devices and methods ... of Dr. Gabriele Niederauer , a seasoned ... Following the recent closure of Series A financing, ... the Surfacer™ Inside-Out Access Catheter System, a proprietary ...
(Date:9/2/2014)... LAUSANNE , Switzerland , ... after receiving ISO 13485 accreditation, Sophia Genetics has become ... mark for the clinical use of a Next Generation Sequencing ... assurance certification represents an important step in raising ... diagnosis, and brings Sophia Genetics, world-leading Data Driven ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO 2Sophia Genetics Becomes the First European Company to Obtain CE-IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing 2
... 20 The District of Columbia Patients, Cooperative ... the District of Columbia, has submitted comments to the ... on proposed regulations announced 45 days ago.   ... http://www.dcpatients.org/DCPC_comments.pdf along with the comments of cannabis ...
... NewBridge Pharmaceuticals FZ-LLC of Dubai, UAE announced today that ... Executive Officer and a member of the company,s Board ... joins NewBridge after a career extending over 29 years ... positions covering many geographies including; US, Europe, and Middle ...
Cached Medicine Technology:DC Patients' Cooperative Urges Changes to the Proposed Medical Cannabis 'Marijuana' Regulations 2NewBridge Pharmaceuticals Completes $12 Million First Close of Series B Financing, Announces Senior Executive Appointments 2NewBridge Pharmaceuticals Completes $12 Million First Close of Series B Financing, Announces Senior Executive Appointments 3
(Date:9/2/2014)... The performance of the Lotteries ... five years. Industry revenue is estimated to grow at ... years through 2014-15, following stabilised growth over the past ... from alternate forms of gambling. Horse and sports betting, ... have all become increasingly popular over the past five ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 The American ... of a Free-Tuition Guarantee for its ICD-10 Medical Coding ... bring the highest level of confidence to students who ... medical coder, but are faced with the uncertainty brought ... implementation of ICD-10 until October 1st, 2015. , AHDPG’s ...
(Date:9/2/2014)... HealthDay Reporter , MONDAY, Sept. 1, ... birth weight are at risk later in life of having ... risk for heart disease, according to a pair of new ... lifetime disadvantages, researchers in both studies -- published online Sept. ... can be overcome. Education appeared to negate the potential ...
(Date:9/2/2014)... 02, 2014 The Jerry Segal Classic ... on September 19 at The ACE Club and Green ... past 25 years, the Classic, organized by the Friends ... for programs and services designed to support patients and ... , “The Segal Classic is a labor of ...
(Date:9/2/2014)... Washington, New York (PRWEB) September 02, 2014 ... LLP announces that Class Counsel has filed ... for service awards in the class action litigation ... Parker Waichman LLP, the Court-Appointed Class Counsel in ... Heimann & Bernstein, LLP; Audet & Partners, LLP; ...
Breaking Medicine News(10 mins):Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 2Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 3Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 2Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 3Health News:The 25th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 3
... 15, 2007, Philadelphia, PA Researchers found that mesalamine ... with a decrease in incidence of colorectal cancer when ... at the 72nd Annual Scientific Meeting of the American ... Detroit matched 16 patients with ulcerative colitis and Crohns ...
... 2007 Post-hoc and other analyses of secondary endpoints ... plc,s (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) ulcerative colitis ... in patients with mild to moderate ulcerative colitis. These ... open-label 12-14 month extension study, are being presented this ...
... toothbrush may be the,ultimate plaque fighting tool, but it ... Sonicare and GfK Roper reveals that more than half,(54 ... fell on,the bathroom floor, despite voting the bathroom as ... percent). In addition, nine percent of men,admitted to reusing ...
... Strengthen Strategic Consulting ... Canada, MOUNTAIN VIEW, Calif., Oct. 15 ... of software,strategic consulting, and regulatory services for optimizing ... scientific consulting,services practices with three new hires. Pharsight ...
... total sleep times, both habitually and on the morning after ... higher than objectively measured sleep times, according to a study ... Clinical Sleep Medicine (JCSM). , Graciela E. Silva, PhD, of ... were 40 years of age or older. The participants ...
... October 15 Sanofi Pasteur, the,vaccines division ... Institut Pasteur to develop a vaccine against ... have access to antigens,identified by Institut Pasteur ... the most deadly malaria infections. Sanofi Pasteur,intends ...
Cached Medicine News:Health News:Mesalamine linked to cancer protection for high risk inflammatory bowel disease patients 2Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 2Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 3Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 4Health News:New Survey Uncovers Dirty Little Secrets About America's Oral Care Habits 2Health News:New Survey Uncovers Dirty Little Secrets About America's Oral Care Habits 3Health News:Pharsight Expands Global Consulting Services Teams 2Health News:Pharsight Expands Global Consulting Services Teams 3Health News:People overestimate their self-reported sleep times compared to measures by a sleep test 2Health News:Sanofi Pasteur and Institut Pasteur Team up Against Malaria 2Health News:Sanofi Pasteur and Institut Pasteur Team up Against Malaria 3
... The dual lumen ... a 1.2 mm inner ... ,Dual oval lumen catheters ... while maintaining maximum catheter ...
The mid-sized titanium port is about 3/4 the diameter and half the weight of the standard model. The silicone catheter has an I.D. of 1.0 mm....
The WaveMap provides immediate clinical decision making information with automatic calculation of pressure gradients and FFR measurements.,SmartWire Pressure Guide Wire - The intelligent choice in ...
... Used for vascular access. ... facilitates single wall puncture with ... sideport is visualized while maintaining ... Sideport exits the hub of ...
Medicine Products: